Business & Economics

Featured Image - Laboratory. Courtesy 2019 Fotolia

Shanghai Miracogen and Synaffix Confirm Expansion of License Agreement

Netherlands-based biotech company Synaffix earlier today confirmed the expansion of a license agreement with Shanghai Miracogen, a Chinese biotechnology...

FDA Approves Trastuzumab Deruxtecan for Unresectable or Metastatic HER2-positive Breast Cancer

The U.S. Food and Drug Administration (FDA) has approved fam-trastuzumab deruxtecan-nxki (Enhertu®; Daiichi Sankyo and AstraZeneca)*, a HER2 directed...

Accelerated Approval for Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer

The U.S. Food and Drug Administration (FDA) granted accelerated approval to enfortumab vedotin-ejfv (Padcev™; Astellas Pharma / Seattle Genetics)*...
Featured Image: Laboratory Glass works. Courtesy: © 2010 - 2018. Fotolia Used with permission.

Immunomedics Resubmits BLA for Sacituzumab Govitecan

In a statement earlier today, Immunomedics confirmed that the company resubmitted its Biologics License Application (BLA) to the U.S....

ADC Express: Rapid ADC Production from a Single Source

Earlier this year, during the 10th annual World ADC meeting held in San Diego, CA, MilliporeSigma, launched a new...

SOTIO and NBE-Therapeutics to Develop ‘Second’ Next-Generation Antibody-Drug Conjugate

SOTIO, a biotechnology company leading the efforts of PPF Group, one of the largest investment groups in Central and...
Daiichi Sankyo

Daiichi Sankyo to Defend Proprietary Antibody-drug Conjugate Technology

Daiichi Sankyo confirmed that the company has filed a Declaratory Judgement action in the District Court of Delaware in...
Signing Ceremony between Ambrx an NovoCodex. Courtesy 2019 NovoCodex.

Ambrx and Novocodex to Jointly Develop and Commercialize 2nd Antibody-drug Conjugate

Novocodex Biopharmaceuticals, a subsidiary of Zhejiang Medicine, and  Ambrx, a privately-held clinical stage biopharmaceutical company, have confirmed that the...

Immunome and pH Pharma Sign Agreement for the Development of Novel ADCs

South Korea-based pH Pharma, a clinical stage biopharmaceutical company and U.S.-based Immunome, a biotechnology company developing first-in-class antibodies as...
On October 16, 2019 Novocodex Biopharmaceuticals, a subsidiary of Zhejiang Medicine, and WuXi Biologics signed a strategic partnership for Phase III clinical trial production of ARX788 as well ongoing large-scale commercial production of the innovative antibody-drug conjugate.

WuXi Biologics Opens New Facility to Supports Novocodex ADC Manufacturing

Earlier this month China-based Contract Research Organization (CRO) WuXi Biologics started commercial production at the company's new Current Good...